MediciNova flops in PhII methamphetamine dependence trial, stock slips
San Diego drugmaker MediciNova has flunked a mid-stage trial testing its lead drug candidate against methamphetamine dependence, sending the company’s stock quickly south in pre …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.